SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-021373
Filing Date
2023-05-11
Accepted
2023-05-11 17:09:35
Documents
77
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acor-20230331.htm   iXBRL 10-Q 1733184
2 EX-31.1 acor-ex31_1.htm EX-31.1 14068
3 EX-31.2 acor-ex31_2.htm EX-31.2 12864
4 EX-32.1 acor-ex32_1.htm EX-32.1 8144
5 EX-32.2 acor-ex32_2.htm EX-32.2 8229
  Complete submission text file 0000950170-23-021373.txt   8358965

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT acor-20230331_def.xml EX-101.DEF 231591
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acor-20230331_pre.xml EX-101.PRE 391980
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acor-20230331_lab.xml EX-101.LAB 536752
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acor-20230331.xsd EX-101.SCH 61649
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT acor-20230331_cal.xml EX-101.CAL 53840
71 EXTRACTED XBRL INSTANCE DOCUMENT acor-20230331_htm.xml XML 1577022
Mailing Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965
Business Address TWO BLUE HILL PLAZA PEARL RIVER NY 10965 914-347-4300
Acorda Therapeutics, Inc. (Filer) CIK: 0001008848 (see all company filings)

IRS No.: 133831168 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-31938 | Film No.: 23912145
SIC: 2836 Biological Products, (No Diagnostic Substances)